An Official Website of the United States Government
Company Information:
Name:
SELEXYS PHARMACEUTICALS CORPORATION
Address:
840 RESEARCH PKWY, STE 516
OKLAHOMA CITY, OK 73104-3601
OKLAHOMA CITY, OK 73104-3601
Located in HUBZone:
No
Woman-Owned:
No
Minority-Owned:
No
URL:
N/A
Phone:
N/A
Award Totals:
Award List:
PEGylation of a Glycosulfopeptide Anti-Inflammatory
Award Year / Program / Phase:
2004 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Ziad Kawar
Award Amount:
$304,843.00
Abstract:
DESCRIPTION (provided by applicant): Normal recruitment of circulating white blood cells (leukocytes) into tissues is important in inflammation, lymphocyte homing, and immunological responses. The mechanism of recruitment involves receptors termed selectins that recognize their counter receptors on… More
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea
Award Year / Program / Phase:
2009 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Scott A. Rollins
Award Amount:
$3,342,787.00
Abstract:
DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. P-selectin mediates the first step i
n the recruitment of white blood cells to… More
Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease
Award Year / Program / Phase:
2010 / SBIR / Phase I
Agency:
HHS
Principal Investigator:
Scott A. Rollins
Award Amount:
$3,113,969.00
Abstract:
DESCRIPTION (provided by applicant): The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory bowel disease. Crohn's Disease is a chronic inflammatory dis
order of the gastrointestinal tract that… More
Development of an Anti-PSGL-1 Antibody to Treat Crohn's Disease
Award Year / Program / Phase:
2011 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Scott A. Rollins – 203-776-1790
Award Amount:
$2,553,342.00
Abstract:
DESCRIPTION (provided by applicant): The primary objective of this proposal is to develop and commercialize a safe and more effective therapy for the treatment of Crohn's Disease, an inflammatory bowel disease. Crohn's Disease is a chronic inflammatory disorder of the gastrointestinal… More
Development of an Anti-P-selectin Antibody for the Treatment of Sickle Cell Disea
Award Year / Program / Phase:
2012 / SBIR / Phase II
Agency:
HHS
Principal Investigator:
Scott A. Rollins – 203-776-1790
Award Amount:
$3,112,914.00
Abstract:
DESCRIPTION (provided by applicant): Selexys Pharmaceuticals is developing a humanized monoclonal antibody drug called SelG1 directed against P-selectin for the treatment of vasoocclusive crisis in patients with sickle cell disease. The ultimate goal of this Phase IIB proposal is to further advance… More